<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02770365</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-NY-15-007</org_study_id>
    <nct_id>NCT02770365</nct_id>
  </id_info>
  <brief_title>Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Padagis LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Impax Laboratories, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Padagis LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare safety and efficacy of Perrigo's drug product compared to an FDA approved drug&#xD;
      product in the treatment of vulvar and vaginal atrophy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Identified as Responders</measure>
    <time_frame>Day 8</time_frame>
    <description>A responder is a subject meeting specific vaginal cytology criteria AND a vaginal pH &lt; 5.0 with a change from Visit 1 of at least 0.5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Most Bothersome Symptom</measure>
    <time_frame>Day 8</time_frame>
    <description>Percentage of subjects based on the improvement (change from Visit 2) of the Most Bothersome Symptom at Visit 3.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">695</enrollment>
  <condition>Atrophy</condition>
  <arm_group>
    <arm_group_label>Test Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>estradiol cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>estradiol cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estrace cream (Perrigo)</intervention_name>
    <arm_group_label>Test Product</arm_group_label>
    <other_name>Perrigo product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estrace cream (Reference)</intervention_name>
    <arm_group_label>Reference Product</arm_group_label>
    <other_name>Reference Listed Drug product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo cream</intervention_name>
    <arm_group_label>Placebo product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  postmenopausal female and otherwise healthy, 30 - 75 years of age.&#xD;
&#xD;
          -  ≤ 5% superficial cells on vaginal smear cytology at Visit 1/Screening.&#xD;
&#xD;
          -  vaginal pH &gt; 5.0 at Visit 1/Screening&#xD;
&#xD;
          -  Have at least one self-assessed moderate to severe symptom of Vulvar and Vaginal&#xD;
             Atrophy identified by the subject as being the most bothersome&#xD;
&#xD;
          -  For women with an intact uterus, vaginal ultrasonography confirmation at Visit&#xD;
             1/Screening of an inactive endometrial lining with an endometrial thickness less than&#xD;
             4 mm.&#xD;
&#xD;
          -  Systolic blood pressure no greater than 150 mm Hg and diastolic blood pressure no&#xD;
             greater than 90 mm Hg at Visit 1/Screening and at Visit 2/Randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Undiagnosed vaginal bleeding or a history of significant risk factors for endometrial&#xD;
             cancer.&#xD;
&#xD;
          -  Known, suspected, or history of cancer of the breast or mammogram indicating any&#xD;
             abnormalities or subject has a history of cervical cancer.&#xD;
&#xD;
          -  Vaginal ultrasonography for all women with an intact uterus confirming endometrial&#xD;
             thickness of 4mm or more&#xD;
&#xD;
          -  History of hypersensitivity or allergy to estradiol or any of the other study&#xD;
             medication ingredients.&#xD;
&#xD;
          -  Known or suspected estrogen-dependent neoplasia.&#xD;
&#xD;
          -  Has deep vein thrombosis, pulmonary embolism or history of these conditions.&#xD;
&#xD;
             • Subject has active arterial thromboembolic disease (e. g. stroke, myocardial&#xD;
             infarction) or history of these conditions.&#xD;
&#xD;
          -  Known acute or chronic hepatic disease or dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Comprehensive Clinical Trials, LLC</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 10, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2016</study_first_posted>
  <results_first_submitted>May 26, 2020</results_first_submitted>
  <results_first_submitted_qc>July 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 11, 2020</results_first_posted>
  <disposition_first_submitted>December 15, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>December 15, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 16, 2016</disposition_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 8, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02770365/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 8, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02770365/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test Product</title>
          <description>estradiol cream&#xD;
estrace cream (Perrigo)</description>
        </group>
        <group group_id="P2">
          <title>Reference Product</title>
          <description>estradiol cream&#xD;
estrace cream (Reference)</description>
        </group>
        <group group_id="P3">
          <title>Placebo Product</title>
          <description>Placebo cream&#xD;
Placebo cream</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="277"/>
                <participants group_id="P2" count="279"/>
                <participants group_id="P3" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="272"/>
                <participants group_id="P2" count="275"/>
                <participants group_id="P3" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test Product</title>
          <description>estradiol cream&#xD;
estrace cream (Perrigo)</description>
        </group>
        <group group_id="B2">
          <title>Reference Product</title>
          <description>estradiol cream&#xD;
estrace cream (Reference)</description>
        </group>
        <group group_id="B3">
          <title>Placebo Product</title>
          <description>Placebo cream&#xD;
Placebo cream</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="275"/>
            <count group_id="B2" value="277"/>
            <count group_id="B3" value="139"/>
            <count group_id="B4" value="691"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.3" spread="6.35"/>
                    <measurement group_id="B2" value="59.9" spread="6.31"/>
                    <measurement group_id="B3" value="59.2" spread="6.06"/>
                    <measurement group_id="B4" value="59.9" spread="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="275"/>
                    <measurement group_id="B2" value="277"/>
                    <measurement group_id="B3" value="139"/>
                    <measurement group_id="B4" value="691"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="143"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="110"/>
                    <measurement group_id="B4" value="548"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="233"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="114"/>
                    <measurement group_id="B4" value="582"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Identified as Responders</title>
        <description>A responder is a subject meeting specific vaginal cytology criteria AND a vaginal pH &lt; 5.0 with a change from Visit 1 of at least 0.5.</description>
        <time_frame>Day 8</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>estradiol cream&#xD;
estrace cream (Perrigo)</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>estradiol cream&#xD;
estrace cream (Reference)</description>
          </group>
          <group group_id="O3">
            <title>Placebo Product</title>
            <description>Placebo cream&#xD;
Placebo cream</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Identified as Responders</title>
          <description>A responder is a subject meeting specific vaginal cytology criteria AND a vaginal pH &lt; 5.0 with a change from Visit 1 of at least 0.5.</description>
          <population>Per protocol population</population>
          <units>percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8"/>
                    <measurement group_id="O2" value="32.0"/>
                    <measurement group_id="O3" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>provides 85% power of success</non_inferiority_desc>
            <param_type>Equivalence ratio</param_type>
            <param_value>1.14</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.92</ci_lower_limit>
            <ci_upper_limit>12.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Most Bothersome Symptom</title>
        <description>Percentage of subjects based on the improvement (change from Visit 2) of the Most Bothersome Symptom at Visit 3.</description>
        <time_frame>Day 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>estradiol cream&#xD;
estrace cream (Perrigo)</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>estradiol cream&#xD;
estrace cream (Reference)</description>
          </group>
        </group_list>
        <measure>
          <title>Most Bothersome Symptom</title>
          <description>Percentage of subjects based on the improvement (change from Visit 2) of the Most Bothersome Symptom at Visit 3.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>the proportion of subjects with treatment success based on the improvement of the Most Bothersome Symptom (MBS) of vulvo-vaginal atrophy at Day 8.</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>Wald's method</method>
            <param_type>equivalence ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.35</ci_lower_limit>
            <ci_upper_limit>4.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test Product</title>
          <description>estradiol cream&#xD;
estrace cream (Perrigo)</description>
        </group>
        <group group_id="E2">
          <title>Reference Product</title>
          <description>estradiol cream&#xD;
estrace cream (Reference)</description>
        </group>
        <group group_id="E3">
          <title>Placebo Product</title>
          <description>Placebo cream&#xD;
Placebo cream</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI's cannot disclose trial results under any circumstances.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director</name_or_title>
      <organization>Perrigo</organization>
      <phone>718-960-9900</phone>
      <email>jonathan.schwartz@perrigo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

